Literature DB >> 26346348

Mcl-1 downregulation leads to the heightened sensitivity exhibited by BCR-ABL positive ALL to induction of energy and ER-stress.

Guy J Leclerc1, Joanna DeSalvo2, Jianfeng Du2, Ningguo Gao3, Gilles M Leclerc1, Mark A Lehrman3, Theodore J Lampidis4, Julio C Barredo5.   

Abstract

BCR-ABL positive (+) acute lymphoblastic leukemia (ALL) accounts for ∼30% of cases of ALL. We recently demonstrated that 2-deoxy-d-glucose (2-DG), a dual energy (glycolysis inhibition) and ER-stress (N-linked-glycosylation inhibition) inducer, leads to cell death in ALL via ER-stress/UPR-mediated apoptosis. Among ALL subtypes, BCR-ABL+ ALL cells exhibited the highest sensitivity to 2-DG suggesting BCR-ABL expression may be linked to this increased vulnerability. To confirm the role of BCR-ABL, we constructed a NALM6/BCR-ABL stable cell line and found significant increase in 2-DG-induced apoptosis compared to control. We found that Mcl-1 was downregulated by agents inducing ER-stress and Mcl-1 levels correlated with ALL sensitivity. In addition, we showed that Mcl-1 expression is positively regulated by the MEK/ERK pathway, dependent on BCR-ABL, and further downregulated by combining ER-stressors with TKIs. We determined that energy/ER stressors led to translational repression of Mcl-1 via the AMPK/mTOR and UPR/PERK/eIF2α pathways. Taken together, our data indicate that BCR-ABL+ ALL exhibits heightened sensitivity to induction of energy and ER-stress through inhibition of the MEK/ERK pathway, and translational repression of Mcl-1 expression via AMPK/mTOR and UPR/PERK/eIF2α pathways. This study supports further consideration of strategies combining energy/ER-stress inducers with BCR-ABL TKIs for future clinical translation in BCR-ABL+ ALL patients.
Copyright © 2015 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  2-deoxy-d-glucose; AMPK; Acute lymphoblastic leukemia; Apoptosis; BCR-ABL+; Combination targeted therapy; Dasatinib; ER stress; ERK; Energy stress; Imatinib; Leukemia; Mcl-1; Tyrosine kinase inhibitors; UPR; eIF2α; shRNA

Year:  2015        PMID: 26346348      PMCID: PMC4783293          DOI: 10.1016/j.leukres.2015.08.007

Source DB:  PubMed          Journal:  Leuk Res        ISSN: 0145-2126            Impact factor:   3.156


  48 in total

1.  Folylpolyglutamate synthetase gene transcription is regulated by a multiprotein complex that binds the TEL-AML1 fusion in acute lymphoblastic leukemia.

Authors:  Guy J Leclerc; Christopher Sanderson; Stephen Hunger; Meenakshi Devidas; Julio C Barredo
Journal:  Leuk Res       Date:  2010-06-09       Impact factor: 3.156

2.  AMPK and Akt determine apoptotic cell death following perturbations of one-carbon metabolism by regulating ER stress in acute lymphoblastic leukemia.

Authors:  Jeffim N Kuznetsov; Guy J Leclerc; Gilles M Leclerc; Julio C Barredo
Journal:  Mol Cancer Ther       Date:  2011-01-24       Impact factor: 6.261

3.  CCR 20th Anniversary commentary: in search of cetuximab's first indication-combination therapy with irinotecan in colorectal cancer.

Authors:  Daniel J Hicklin
Journal:  Clin Cancer Res       Date:  2015-04-01       Impact factor: 12.531

Review 4.  Detection of resistance to imatinib by metabolic profiling: clinical and drug development implications.

Authors:  Natalie Serkova; László G Boros
Journal:  Am J Pharmacogenomics       Date:  2005

Review 5.  Bortezomib as the first proteasome inhibitor anticancer drug: current status and future perspectives.

Authors:  D Chen; M Frezza; S Schmitt; J Kanwar; Q P Dou
Journal:  Curr Cancer Drug Targets       Date:  2011-03       Impact factor: 3.428

6.  CCR 20th anniversary commentary: BMS-247550—microtubule stabilization as successful targeted therapy.

Authors:  Navjotsingh Pabla; Alex Sparreboom
Journal:  Clin Cancer Res       Date:  2015-03-15       Impact factor: 12.531

7.  Development and maintenance of B and T lymphocytes requires antiapoptotic MCL-1.

Authors:  Joseph T Opferman; Anthony Letai; Caroline Beard; Mia D Sorcinelli; Christy C Ong; Stanley J Korsmeyer
Journal:  Nature       Date:  2003-12-11       Impact factor: 49.962

8.  Under normoxia, 2-deoxy-D-glucose elicits cell death in select tumor types not by inhibition of glycolysis but by interfering with N-linked glycosylation.

Authors:  Metin Kurtoglu; Ningguo Gao; Jie Shang; Johnathan C Maher; Mark A Lehrman; Medhi Wangpaichitr; Niramol Savaraj; Andrew N Lane; Theodore J Lampidis
Journal:  Mol Cancer Ther       Date:  2007-11       Impact factor: 6.261

9.  Mechanistic rationale for targeting the unfolded protein response in pre-B acute lymphoblastic leukemia.

Authors:  Behzad Kharabi Masouleh; Huimin Geng; Christian Hurtz; Lai N Chan; Aaron C Logan; Mi Sook Chang; Chuanxin Huang; Srividya Swaminathan; Haibo Sun; Elisabeth Paietta; Ari M Melnick; Phillip Koeffler; Markus Müschen
Journal:  Proc Natl Acad Sci U S A       Date:  2014-05-12       Impact factor: 11.205

10.  Regulation of AKT phosphorylation at Ser473 and Thr308 by endoplasmic reticulum stress modulates substrate specificity in a severity dependent manner.

Authors:  Hong Wa Yung; D Stephen Charnock-Jones; Graham J Burton
Journal:  PLoS One       Date:  2011-03-21       Impact factor: 3.240

View more
  5 in total

1.  Inhibition of the NEDD8 conjugation pathway induces calcium-dependent compensatory activation of the pro-survival MEK/ERK pathway in acute lymphoblastic leukemia.

Authors:  Shuhua Zheng; Gilles M Leclerc; Bin Li; Ronan T Swords; Julio C Barredo
Journal:  Oncotarget       Date:  2017-12-31

2.  By reducing global mRNA translation in several ways, 2-deoxyglucose lowers MCL-1 protein and sensitizes hemopoietic tumor cells to BH3 mimetic ABT737.

Authors:  Maximilien Tailler; Lisa M Lindqvist; Leonie Gibson; Jerry M Adams
Journal:  Cell Death Differ       Date:  2018-12-11       Impact factor: 15.828

Review 3.  The Unfolded Protein Response: A Novel Therapeutic Target in Acute Leukemias.

Authors:  Alberto M Martelli; Francesca Paganelli; Francesca Chiarini; Camilla Evangelisti; James A McCubrey
Journal:  Cancers (Basel)       Date:  2020-02-01       Impact factor: 6.639

Review 4.  mTOR Regulation of Metabolism in Hematologic Malignancies.

Authors:  Simone Mirabilii; Maria Rosaria Ricciardi; Agostino Tafuri
Journal:  Cells       Date:  2020-02-11       Impact factor: 6.600

5.  LncRNA H19 inhibits ER stress induced apoptosis and improves diabetic cardiomyopathy by regulating PI3K/AKT/mTOR axis.

Authors:  Sixuan Wang; Jun Duan; Jiangquan Liao; Yan Wang; Xiang Xiao; Lin Li; Yi Liu; Huan Gu; Peng Yang; Dongliang Fu; Jinhang Du; Xianlun Li; Mingjing Shao
Journal:  Aging (Albany NY)       Date:  2022-08-30       Impact factor: 5.955

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.